Toll样受体家族在肝脏缺血再灌注损伤中的研究进展  

Progress of the Toll-like receptor family in hepatic ischemia-reperfusion injury

作　　者：卢想 谭思由 张鑫 魏来[1] 陈文雁[1] LU Xiang;TAN Siyou;ZHANG Xin(Department of Anesthesiology,People’s Hospital of Hunan Province(the First Affiliated Hospital of Hunan Normal University),Hunan,Changsha 410005,China)

机构地区：[1]湖南省人民医院(湖南师范大学附属第一医院)麻醉科,长沙市410005

出　　处：《河北医药》2024年第18期2842-2847,共6页Hebei Medical Journal

基　　金：湖南省自然科学基金面上项目(编号:2022JJ30341)。

摘　　要：肝脏缺血再灌注损伤(HIRI)是肝胆术后、休克和创伤发生后肝功能受损的主要原因,严重影响患者的预后。减轻HIRI不仅有利于术后患者的恢复,还可以提高患者的存活率。然而,HIRI涉及到的机制极其复杂,目前缺乏切实有效的防治措施,这依赖于对HIRI病理生理机制的深入探索。近年来,Toll样受体(TLRs)被证实参与了HIRI的重要分子,通过调控TLRs可能发挥防治HIRI的有益作用。本文旨在阐述TLRs参与HIRI的机制进展,总结基于TLRs改善HIRI的新兴治疗策略,为临床防治HIRI、药物开发和管理策略提供思路和理论依据。Hepatic ischemia-reperfusion injury(HIRI)is the main cause of impaired liver function after hepatobiliary surgery,shock and traumatization,which seriously affects the prognosis.Alleviating HIRI not only facilitates postoperative recovery,but also improves the survival rate.However,the mechanisms involved in HIRI are extremely complex.Effective preventive and curative measures for HIRI are currently lacked.It is important to perform an in-depth exploration of the pathophysiological mechanisms of HIRI.In recent years,Toll-like receptors(TLRs)have been validated to be involved in HIRI,which may play a beneficial role in attenuating HIRI.This review aims to elaborate the latest research progress of TLRs involved in HIRI,as well as to outline the emerging therapeutic strategies to improve HIRI through TLRs,so as to provide ideas and theoretical basis for clinical control of HIRI,drug development and management strategies.

关 键 词：肝脏缺血再灌注损伤 分子机制 TOLL样受体 炎症反应 

分 类 号：R392[医药卫生—免疫学]